Investing In CBD Stocks Offers Opportunity But Risks

  • 📰 Forbes
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 53%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

There is a lot of hype regarding CBD and a lack of regulatory clarity. I discuss the big issues and identify some of the better players in the space among public-traded companies.

Cannabidiol has taken off lately, and the recent passage of the Farm Act in December has accelerated interest in the cannabinoid found in cannabis plants that was also the active ingredient in the first FDA approved drug derived from botanical cannabis, GW Pharmaceuticals's Epidiolex, which is indicated for the treatment of seizures in treatment-resistant forms of two types of epilepsy, Dravet syndrome and Lennox-Gastaut syndrome.

The recent Farm Act that legalized industrial hemp was supposed to clear the path for the sale of CBD from industrial hemp, but this is only at the federal level. It turns out that states must create legislation to govern hemp production and the commercialization of hemp.

Gottlieb had recently announced that the agency would hold public hearings on the issue in April. His pending departure throws into question how this will all play out, so uncertainty will persist for a while.With the tremendous growth in the market, investors have expressed keen interest in CBD, and the number of publicly-traded stocks has skyrocketed.

 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

starzwithfeet Invest in THC - that’s better

shall review

You don’t say

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 394. in KR

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Cannabis stocks tumble as FDA chief’s departure leaves CBD regulation in limboCannabis stocks fall as investors weigh the surprise news that the head of the U.S. Food and Drug Administration has resigned, leaving the fate of the cannabis ingredient CBD in regulatory limbo.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »

With CBD, Cannabis Wellness Market Goes BigSales of CBD are predicted to hit $22 billion in 3 years—and much of that projected growth is coming from CBD’s newly minted status as a health and wellness product Even agrees, Shalini_bh and we are not allowed to purchase it in South Dakota🙁 just wait till there is a federal tax on that.
출처: Forbes - 🏆 394. / 53 더 많은 것을 읽으십시오 »

FDA chief Scott Gottlieb's resignation leaves 'billion-dollar question' for CBD industryJust a week ago, it looked like the Food and Drug Administration was ready to revisit its policies around CBD-infused food and drinks. Coors cannabis JV partner HEXO creating Truss Beverages 🍺
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »

This investing app lets anyone with $50 invest in companies that make money by doing goodSwell is an impact investing app that's based on the idea that today’s biggest challenges will result in tomorrow’s leading industries.
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »

Cannabis stocks tumble as FDA chief’s departure leaves CBD regulation in limboCannabis stocks fall as investors weigh the surprise news that the head of the U.S. Food and Drug Administration has resigned, leaving the fate of the cannabis ingredient CBD in regulatory limbo.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »